Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Celltrion has entered into a platform technology licensing agreement with Korean biotech TRiOar for its tumor microenvironment-selective activation platform ‘TROCAD™’, securing exclusive development rights for up to 6 targets worth up to approx. KRW 522.0B including upfront and milestone payments.
📊 [Key Disclosure Details & Financial Summary]
- Disclosure Title: Execution of Platform Technology License Agreement with TRiOar (Major Management Matters)
- Counterparty: TRiOar Inc. (Korea)
- Contract / Confirmation Date: November 19, 2025
- Contract Details:
- Licensing agreement for TRiOar’s TROCAD™ (TRiOar Conditional Activatable Domain) platform technology, which selectively activates in tumor microenvironments
- Acquisition of exclusive development and commercialization rights for up to 6 targets
- Contract Period: From the execution date until the expiration date of the latest patent right associated with the licensed technology or product
- Contract Values (Applied Exchange Rate: Basic rate on 2025-11-19 USD/KRW 1,465.20):
- Upfront Technology Access Fee: KRW 1.0B
- Development Milestones: Up to USD 230,476,000 (approx. KRW 338.0B) if all 6 target rights are exercised (payable upon research, clinical, and regulatory milestones)
- Sales Milestones: Up to USD 124,780,000 (approx. KRW 183.0B) if all 6 target rights are exercised (based on commercial sales benchmarks, assuming all 6 targets achieve $2.0B in revenue)
- Total Potential Value: Approx. KRW 522.0B (Upfront KRW 1.0B + Dev Milestones KRW 338.0B + Sales Milestones KRW 183.0B)
- Royalties: Tiered running royalties of 2.0% ~ 3.5% based on sales volume
- Investment Caution & Risk Factors:
- The contract may be terminated in case of research/development suspension by regulatory authorities or failure in product approval
- Development/sales milestones and royalties are conditional upon achieving specific targets (POC verification, clinical development, approval, and sales targets) and may not be fully paid (no penalty fees incurred if terminated early)
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of Pipeline Development and POC Progress Following Platform Licensing
This disclosure details Celltrion’s license agreement for TRiOar’s TROCAD™ platform to bolster its oncology pipeline, making it important to monitor the progress of initial Proof of Concept (POC) testing and target-specific clinical entries. Tracking R&D developments following technology integration ensures verification of project execution. Pipeline progress, milestone achievements, and key R&D updates can be verified through future regulatory disclosures or upcoming periodic filings (Quarterly, Half-Yearly, or Annual Business Reports).
📢 Disclaimer & Source Information
Source: This content was newly generated and structured based on official data submitted to the Data Analysis, Retrieval and Transfer System (DART) of the Financial Supervisory Service.
Investment Risk Notice: This information is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial responsibilities rest solely with the investor.
Contact: For compliance inquiries or copyright concerns, please contact ksb220805@gmail.com.
